Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Icrucumab||IMC-18F1|IMC18F1||Icrucumab (IMC-18F1) is a monoclonal antibody that binds FLT1 (VEGFR1) to prevent ligand-based activation, which may result in decreased angiogenesis and tumor growth (PMID: 17085673, PMID: 28220020).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Icrucumab||Phase I||Actionable||In a Phase I trial, Icrucumab (IMC-18F1) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (PMID: 23903897).||23903897|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|